Collaborative Practice Agreement · PharmD
Oregon CDTM Protocol for Pharmacists
Recognized but not required in every case. The CDTM Protocol is the written instrument Oregon law names for a Pharmacist working with a physician. Below: the board that governs it, what it must contain, and the terms it has to carry.
Oregon grants pharmacists direct statutory prescriptive authority for a Board-defined formulary (ORS 689.645: diabetic supplies, emergency insulin, albuterol, epinephrine, smoking-cessation aids, etc.) and for hormonal contraceptives (ORS 689.689) — grounded in statute and (for the formulary) a prior diagnosis by another prescriber, not a physician collaboration/CDTM agreement. A separate physician-agreement-based collaborative drug therapy management pathway was not confirmed in this research pass.
What a Oregon CDTM Protocol must contain
Governed by the Oregon Board of Pharmacy. Each numbered item is a statutory requirement the agreement must satisfy.
The Pharmacist may participate in Collaborative Drug Therapy Management ("CDTM") for the Physician's patients only under a written CDTM protocol between the Physician (or the Physician's organized medical group) and the Pharmacist (or the Pharmacist's pharmacy). CDTM is valid only as applied to a drug therapy the Physician has already initiated by a prescription order for the specific patient; the protocol does not authorize the Pharmacist to initiate new drug therapy independent of such an order.
Source: OAR 855-019-0260
The CDTM protocol shall identify the participating pharmacists and practitioners, designate a principal pharmacist and practitioner responsible for its oversight, describe the types of decisions the Pharmacist may make (including the disease and drug categories covered, the procedures to follow, and the documentation and communication methods to use), and set out the training and competency the Pharmacist must have to participate. The protocol may not be used to permit therapeutic substitution outside its terms.
Source: OAR 855-019-0260
- The CDTM Protocol on file also carries 1 scope, 1 registration clauses, generated in the document itself.
Statutes and rules cited
- OAR 855-019-0260regulation
Oregon Board of Pharmacy rule governing Collaborative Drug Therapy Management (CDTM) protocols between a pharmacist and a practitioner.
Terms it has to carry
Ratio, proximity, chart review, meeting and prescribing terms the agreement has to carry, from the state's supervision rules.
Proximity
Not codified — left to the agreement
Supervision ratio
Not codified — no cap on file
Chart review
Not codified — left to the agreement
Meeting cadence
Not codified — left to the agreement
Prescriptive authority
Covered by the practice agreement · no controlled-substance authority
Neither statutory authority researched here extends to DEA-scheduled controlled substances; whether any separate Oregon pharmacist authority reaches controlled substances (e.g. naloxone, which is not scheduled) was not exhaustively checked.
Written agreement
Not required
Unconditional for the statutory formulary/contraceptive authority researched here — no physician agreement is required for either. Whether a distinct, agreement-based collaborative drug therapy management (CDTM) pathway also exists in Oregon (as in many other states) was not confirmed; treat as an open item rather than settled absence.
Practice ownership (corporate practice of medicine)
Non-licensee ownership permitted — Drug outlets register with the State Board of Pharmacy (ORS 689.305) and may be corporate entities — ORS 689.305 contemplates employees of a registered corporation, implying non-pharmacist/corporate ownership is permitted, consistent with the typical 'pharmacist-in-charge retains professional control' model seen in other states. The specific Oregon statute/rule naming a 'pharmacist-in-charge' safeguard was not located in this research pass — confirm before relying on it.
Materially more permissive than the physician/PA/NP/APRN entity-ownership rules above.
Legal sources for these rules (4)
About Oregon's rules
Oregon has no physician-supervision requirement for NP/CNS/CRNA and replaced PA 'supervision' with a non-supervisory 'collaboration agreement' (ORS 677.495-677.525, recodified by H.B. 4010, eff. June 6, 2024). CNM and PMHNP are population foci under the single NP license (OAR 851-050-0005), not separate license categories. CRNA/CNS entity co-ownership with physicians is unconfirmed — ORS 58.376 names only physicians, PAs, and NPs.
Other clinicians in Oregon: see the state overview.